Eric Yee
Concepts (247)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ampulla of Vater | 4 | 2018 | 17 | 0.970 |
Why?
| Intestinal Mucosa | 3 | 2020 | 216 | 0.760 |
Why?
| Cannabidiol | 4 | 2024 | 40 | 0.750 |
Why?
| Colitis | 4 | 2020 | 51 | 0.600 |
Why?
| Gastritis | 1 | 2018 | 32 | 0.590 |
Why?
| Crohn Disease | 4 | 2021 | 93 | 0.580 |
Why?
| Plant Extracts | 4 | 2024 | 174 | 0.580 |
Why?
| Cannabis | 4 | 2024 | 146 | 0.560 |
Why?
| Adenoma, Liver Cell | 1 | 2016 | 9 | 0.520 |
Why?
| Placenta Diseases | 1 | 2016 | 13 | 0.520 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2016 | 23 | 0.510 |
Why?
| Liver | 8 | 2024 | 1132 | 0.500 |
Why?
| Adenosine Deaminase | 3 | 2021 | 4 | 0.370 |
Why?
| Liver Cirrhosis | 3 | 2018 | 229 | 0.370 |
Why?
| Gastrointestinal Agents | 2 | 2021 | 35 | 0.360 |
Why?
| Brenner Tumor | 1 | 2010 | 1 | 0.350 |
Why?
| Magnetic Resonance Imaging | 6 | 2020 | 1548 | 0.340 |
Why?
| Pancreatic Neoplasms | 3 | 2018 | 206 | 0.340 |
Why?
| Immunity, Innate | 3 | 2020 | 105 | 0.330 |
Why?
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 102 | 0.330 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 226 | 0.320 |
Why?
| Mice, Inbred C57BL | 6 | 2024 | 1808 | 0.310 |
Why?
| Adenosine Triphosphatases | 2 | 2017 | 87 | 0.280 |
Why?
| Humans | 33 | 2024 | 50503 | 0.260 |
Why?
| Carcinoma, Renal Cell | 2 | 2020 | 101 | 0.260 |
Why?
| Mice | 12 | 2024 | 5687 | 0.260 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 450 | 0.250 |
Why?
| Common Bile Duct Diseases | 2 | 2015 | 8 | 0.250 |
Why?
| Kidney Neoplasms | 2 | 2020 | 174 | 0.250 |
Why?
| Colitis, Ulcerative | 2 | 2016 | 56 | 0.250 |
Why?
| Membrane Proteins | 2 | 2018 | 332 | 0.240 |
Why?
| Immunohistochemistry | 4 | 2018 | 957 | 0.230 |
Why?
| Lab-On-A-Chip Devices | 1 | 2024 | 9 | 0.230 |
Why?
| Alanine Transaminase | 2 | 2023 | 119 | 0.220 |
Why?
| Acetaminophen | 3 | 2023 | 276 | 0.210 |
Why?
| Liver Diseases | 1 | 2023 | 80 | 0.210 |
Why?
| Colonoscopy | 3 | 2020 | 100 | 0.200 |
Why?
| Animals | 13 | 2024 | 13124 | 0.200 |
Why?
| Male | 21 | 2024 | 25907 | 0.200 |
Why?
| Biopsy | 3 | 2020 | 588 | 0.200 |
Why?
| Female | 19 | 2021 | 27081 | 0.200 |
Why?
| Autocrine Communication | 1 | 2021 | 8 | 0.190 |
Why?
| Kupffer Cells | 1 | 2021 | 11 | 0.190 |
Why?
| Paracrine Communication | 1 | 2021 | 12 | 0.190 |
Why?
| Predictive Value of Tests | 3 | 2020 | 930 | 0.190 |
Why?
| Biological Factors | 1 | 2021 | 10 | 0.190 |
Why?
| Adult | 13 | 2021 | 13577 | 0.180 |
Why?
| Monocytes | 1 | 2021 | 127 | 0.180 |
Why?
| Common Bile Duct Neoplasms | 3 | 2015 | 11 | 0.180 |
Why?
| Liver Neoplasms | 2 | 2015 | 326 | 0.180 |
Why?
| Colon | 2 | 2020 | 97 | 0.180 |
Why?
| Toll-Like Receptor 9 | 1 | 2020 | 10 | 0.180 |
Why?
| Endoscopy, Gastrointestinal | 2 | 2018 | 75 | 0.180 |
Why?
| Enterotoxins | 1 | 2020 | 12 | 0.180 |
Why?
| Bacterial Toxins | 1 | 2020 | 51 | 0.170 |
Why?
| Abdomen | 1 | 2020 | 75 | 0.170 |
Why?
| Apyrase | 2 | 2017 | 17 | 0.170 |
Why?
| Methamphetamine | 1 | 2022 | 194 | 0.170 |
Why?
| Cell Proliferation | 3 | 2018 | 985 | 0.170 |
Why?
| Clostridium Infections | 1 | 2020 | 55 | 0.170 |
Why?
| Methionine | 1 | 2020 | 134 | 0.160 |
Why?
| Gastrointestinal Tract | 1 | 2020 | 103 | 0.160 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 9 | 0.160 |
Why?
| Colonic Pouches | 2 | 2015 | 6 | 0.160 |
Why?
| Lipase | 1 | 2018 | 12 | 0.150 |
Why?
| Claudin-1 | 1 | 2018 | 4 | 0.150 |
Why?
| Zonula Occludens-1 Protein | 1 | 2018 | 7 | 0.150 |
Why?
| Observer Variation | 1 | 2018 | 139 | 0.150 |
Why?
| Cation Transport Proteins | 1 | 2018 | 27 | 0.150 |
Why?
| Transcriptome | 2 | 2020 | 313 | 0.150 |
Why?
| Enteric Nervous System | 1 | 2017 | 1 | 0.150 |
Why?
| Bile Duct Neoplasms | 1 | 2017 | 27 | 0.150 |
Why?
| Cholangiocarcinoma | 1 | 2017 | 25 | 0.150 |
Why?
| Serum | 1 | 2017 | 32 | 0.140 |
Why?
| Liver Regeneration | 1 | 2017 | 47 | 0.140 |
Why?
| Middle Aged | 12 | 2021 | 12611 | 0.140 |
Why?
| Lanthanum | 1 | 2017 | 4 | 0.140 |
Why?
| Upper Gastrointestinal Tract | 1 | 2017 | 4 | 0.140 |
Why?
| Transaminases | 1 | 2017 | 11 | 0.140 |
Why?
| Hyperphosphatemia | 1 | 2017 | 3 | 0.140 |
Why?
| Decision Support Techniques | 1 | 2017 | 70 | 0.140 |
Why?
| Anorexia Nervosa | 1 | 2017 | 6 | 0.140 |
Why?
| Pneumatosis Cystoides Intestinalis | 1 | 2017 | 7 | 0.140 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 125 | 0.140 |
Why?
| Paneth Cells | 1 | 2016 | 1 | 0.140 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 833 | 0.130 |
Why?
| Immunity, Mucosal | 1 | 2016 | 14 | 0.130 |
Why?
| Dietary Supplements | 1 | 2020 | 449 | 0.130 |
Why?
| Retrospective Studies | 5 | 2021 | 6263 | 0.130 |
Why?
| Adaptive Immunity | 1 | 2016 | 32 | 0.130 |
Why?
| Cholangitis, Sclerosing | 1 | 2016 | 9 | 0.130 |
Why?
| Pregnancy, Twin | 1 | 2016 | 6 | 0.130 |
Why?
| Insulinoma | 1 | 2016 | 7 | 0.130 |
Why?
| Diagnosis, Differential | 5 | 2020 | 1033 | 0.130 |
Why?
| Th1 Cells | 1 | 2016 | 53 | 0.130 |
Why?
| Th17 Cells | 1 | 2016 | 25 | 0.130 |
Why?
| Enteral Nutrition | 1 | 2017 | 150 | 0.130 |
Why?
| Hepatitis, Autoimmune | 1 | 2016 | 27 | 0.130 |
Why?
| Incidental Findings | 1 | 2016 | 39 | 0.130 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 31 | 0.130 |
Why?
| Adenomatous Polyposis Coli | 1 | 2015 | 7 | 0.130 |
Why?
| Fatty Acids | 1 | 2016 | 144 | 0.130 |
Why?
| Serine Endopeptidases | 1 | 2016 | 51 | 0.130 |
Why?
| Multidetector Computed Tomography | 1 | 2015 | 7 | 0.130 |
Why?
| Proto-Oncogene Proteins | 1 | 2016 | 145 | 0.120 |
Why?
| Hypoglycemia | 1 | 2016 | 55 | 0.120 |
Why?
| Bariatric Surgery | 1 | 2016 | 42 | 0.120 |
Why?
| Angiomyolipoma | 1 | 2015 | 10 | 0.120 |
Why?
| Tomography, X-Ray Computed | 3 | 2015 | 1164 | 0.120 |
Why?
| Rectal Neoplasms | 1 | 2015 | 51 | 0.120 |
Why?
| Inflammatory Bowel Diseases | 1 | 2015 | 52 | 0.120 |
Why?
| Kwashiorkor | 1 | 2014 | 3 | 0.120 |
Why?
| Antigens, CD | 1 | 2016 | 222 | 0.120 |
Why?
| Macrophages | 1 | 2017 | 364 | 0.120 |
Why?
| Gastric Bypass | 1 | 2014 | 20 | 0.120 |
Why?
| Paraganglioma | 1 | 2014 | 14 | 0.120 |
Why?
| Reproducibility of Results | 1 | 2018 | 1197 | 0.120 |
Why?
| Neoplasms, Muscle Tissue | 1 | 2014 | 11 | 0.110 |
Why?
| Disease Models, Animal | 4 | 2020 | 1436 | 0.110 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2014 | 80 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 3 | 2024 | 1372 | 0.110 |
Why?
| Dacryocystitis | 1 | 2013 | 4 | 0.110 |
Why?
| Aged | 8 | 2021 | 9741 | 0.110 |
Why?
| Nasolacrimal Duct | 1 | 2013 | 11 | 0.110 |
Why?
| Anesthetics, Local | 1 | 2013 | 76 | 0.100 |
Why?
| Colorectal Neoplasms | 1 | 2015 | 260 | 0.100 |
Why?
| Adenocarcinoma | 1 | 2016 | 397 | 0.100 |
Why?
| Cocaine | 1 | 2013 | 182 | 0.100 |
Why?
| Mice, Knockout | 3 | 2020 | 844 | 0.100 |
Why?
| Sensitivity and Specificity | 3 | 2020 | 859 | 0.090 |
Why?
| Sulfonamides | 1 | 2012 | 126 | 0.090 |
Why?
| Cocaine-Related Disorders | 1 | 2013 | 209 | 0.090 |
Why?
| Pyrimidines | 1 | 2012 | 191 | 0.090 |
Why?
| Protein Kinase Inhibitors | 1 | 2012 | 204 | 0.090 |
Why?
| Rats, Wistar | 2 | 2022 | 224 | 0.090 |
Why?
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2010 | 4 | 0.090 |
Why?
| CA-125 Antigen | 1 | 2010 | 16 | 0.090 |
Why?
| Carcinoembryonic Antigen | 1 | 2010 | 12 | 0.090 |
Why?
| Pregnancy | 1 | 2016 | 2452 | 0.080 |
Why?
| Postoperative Complications | 1 | 2015 | 1033 | 0.080 |
Why?
| Prospective Studies | 3 | 2021 | 2378 | 0.080 |
Why?
| Dextran Sulfate | 2 | 2017 | 10 | 0.070 |
Why?
| Liver Function Tests | 2 | 2017 | 45 | 0.060 |
Why?
| Rats | 2 | 2022 | 3292 | 0.060 |
Why?
| Bilirubin | 1 | 2024 | 40 | 0.060 |
Why?
| Young Adult | 3 | 2020 | 4102 | 0.060 |
Why?
| Species Specificity | 1 | 2024 | 187 | 0.060 |
Why?
| Disease Progression | 2 | 2018 | 829 | 0.060 |
Why?
| Pyruvic Acid | 1 | 2023 | 21 | 0.050 |
Why?
| Alanine | 1 | 2023 | 43 | 0.050 |
Why?
| Case-Control Studies | 2 | 2017 | 1156 | 0.050 |
Why?
| Hepatocytes | 1 | 2024 | 178 | 0.050 |
Why?
| Adolescent | 3 | 2020 | 6443 | 0.050 |
Why?
| Oxidation-Reduction | 1 | 2023 | 316 | 0.050 |
Why?
| Signal Transduction | 2 | 2020 | 1624 | 0.050 |
Why?
| Glutathione | 1 | 2023 | 299 | 0.050 |
Why?
| Amphetamine | 1 | 2022 | 38 | 0.050 |
Why?
| Half-Life | 1 | 2022 | 86 | 0.050 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2021 | 9 | 0.050 |
Why?
| Aged, 80 and over | 2 | 2020 | 3226 | 0.050 |
Why?
| Anti-Bacterial Agents | 2 | 2020 | 745 | 0.050 |
Why?
| Antioxidants | 1 | 2023 | 239 | 0.050 |
Why?
| Mucin-2 | 1 | 2020 | 8 | 0.040 |
Why?
| Drug Monitoring | 1 | 2020 | 79 | 0.040 |
Why?
| Treatment Outcome | 2 | 2021 | 5283 | 0.040 |
Why?
| Ileum | 1 | 2020 | 85 | 0.040 |
Why?
| Molecular Chaperones | 1 | 2020 | 61 | 0.040 |
Why?
| Adenosylhomocysteinase | 1 | 2020 | 9 | 0.040 |
Why?
| Alcohol Dehydrogenase | 1 | 2020 | 37 | 0.040 |
Why?
| Aldehyde Dehydrogenase | 1 | 2020 | 25 | 0.040 |
Why?
| Chemokines | 1 | 2020 | 75 | 0.040 |
Why?
| DNA, Bacterial | 1 | 2020 | 186 | 0.040 |
Why?
| Epithelial Cells | 1 | 2021 | 207 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 160 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 151 | 0.040 |
Why?
| Oxidative Stress | 1 | 2023 | 772 | 0.040 |
Why?
| Lipoproteins, VLDL | 1 | 2018 | 9 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 517 | 0.040 |
Why?
| Lipoproteins, HDL | 1 | 2018 | 18 | 0.040 |
Why?
| Evaluation Studies as Topic | 1 | 2017 | 107 | 0.040 |
Why?
| Drug Overdose | 1 | 2020 | 159 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2018 | 51 | 0.040 |
Why?
| Neoplasm Grading | 1 | 2017 | 122 | 0.040 |
Why?
| Dexamethasone | 1 | 2020 | 432 | 0.040 |
Why?
| Bile Ducts | 1 | 2017 | 49 | 0.040 |
Why?
| Refeeding Syndrome | 1 | 2017 | 1 | 0.040 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2018 | 244 | 0.040 |
Why?
| Risk Factors | 2 | 2016 | 3724 | 0.030 |
Why?
| RNA, Messenger | 1 | 2020 | 1089 | 0.030 |
Why?
| ROC Curve | 1 | 2017 | 226 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2020 | 978 | 0.030 |
Why?
| Hepatitis | 1 | 2017 | 21 | 0.030 |
Why?
| Cytokines | 1 | 2020 | 606 | 0.030 |
Why?
| Cell Movement | 1 | 2018 | 247 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 625 | 0.030 |
Why?
| Genotype | 1 | 2018 | 533 | 0.030 |
Why?
| Transcription, Genetic | 1 | 2018 | 361 | 0.030 |
Why?
| Lipoproteins, LDL | 1 | 2018 | 170 | 0.030 |
Why?
| Receptor, Adenosine A2A | 1 | 2016 | 3 | 0.030 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2016 | 49 | 0.030 |
Why?
| Phosphoric Diester Hydrolases | 1 | 2016 | 33 | 0.030 |
Why?
| Interleukin-17 | 1 | 2016 | 37 | 0.030 |
Why?
| Malnutrition | 1 | 2017 | 85 | 0.030 |
Why?
| Anastomosis, Surgical | 1 | 2015 | 66 | 0.030 |
Why?
| Postoperative Period | 1 | 2016 | 171 | 0.030 |
Why?
| Carcinoma in Situ | 1 | 2016 | 73 | 0.030 |
Why?
| Colonic Polyps | 1 | 2015 | 37 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2018 | 475 | 0.030 |
Why?
| Organometallic Compounds | 1 | 2015 | 42 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2018 | 746 | 0.030 |
Why?
| Endoscopy | 1 | 2016 | 119 | 0.030 |
Why?
| Obesity, Morbid | 1 | 2016 | 78 | 0.030 |
Why?
| Pancreatic Function Tests | 1 | 2014 | 2 | 0.030 |
Why?
| Malabsorption Syndromes | 1 | 2014 | 9 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 511 | 0.030 |
Why?
| Image Enhancement | 1 | 2015 | 54 | 0.030 |
Why?
| Kidney Failure, Chronic | 1 | 2017 | 201 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 572 | 0.030 |
Why?
| Models, Biological | 1 | 2018 | 716 | 0.030 |
Why?
| Blotting, Western | 1 | 2016 | 578 | 0.030 |
Why?
| Population Surveillance | 1 | 2015 | 164 | 0.030 |
Why?
| Mammary Glands, Human | 1 | 2014 | 14 | 0.030 |
Why?
| Early Detection of Cancer | 1 | 2016 | 163 | 0.030 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2014 | 31 | 0.030 |
Why?
| Recurrence | 1 | 2016 | 659 | 0.030 |
Why?
| Contrast Media | 1 | 2015 | 192 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2018 | 1398 | 0.030 |
Why?
| Gene Expression | 1 | 2016 | 610 | 0.030 |
Why?
| Body Mass Index | 1 | 2017 | 677 | 0.030 |
Why?
| Lacrimal Duct Obstruction | 1 | 2013 | 7 | 0.030 |
Why?
| Azithromycin | 1 | 2013 | 25 | 0.030 |
Why?
| Fluoroquinolones | 1 | 2013 | 24 | 0.030 |
Why?
| Administration, Intranasal | 1 | 2013 | 30 | 0.030 |
Why?
| Dacryocystorhinostomy | 1 | 2013 | 11 | 0.030 |
Why?
| Flow Cytometry | 1 | 2016 | 474 | 0.030 |
Why?
| Mass Screening | 1 | 2015 | 344 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2017 | 1610 | 0.020 |
Why?
| Indazoles | 1 | 2012 | 46 | 0.020 |
Why?
| Fatal Outcome | 1 | 2012 | 197 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 182 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2013 | 641 | 0.020 |
Why?
| Prognosis | 1 | 2016 | 1978 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2016 | 2242 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 2935 | 0.020 |
Why?
| Infant | 1 | 2016 | 3628 | 0.020 |
Why?
| Child, Preschool | 1 | 2016 | 3942 | 0.020 |
Why?
| Child | 1 | 2016 | 6906 | 0.010 |
Why?
|
|
Yee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|